Sprott Inc’s Gain Therapeutics GANX Stock Holding History

Sprott Inc’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,000	Closed	-$38.6K	–	247
2025 Q4	$38.6K	Buy	+12,000	New	+$32K	﹤0.01%	210
2025 Q2	–	Sell	-14,000	Closed	-$26.7K	–	215
2025 Q1	$26.7K	Hold	14,000	–	–	﹤0.01%	186
2024 Q4	$30.2K	Buy	+14,000	New	+$28.1K	﹤0.01%	180

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Sprott Inc's GANX Position: Q1 2026 in Review

Sprott Inc sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 12,000 shares — an estimated $38.6K sold.

Sprott Inc first reported a position in GANX in Q4 2024 and held it in 3 quarters. The position peaked at $38.6K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Sprott Inc reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
Sprott Inc sold 12,000 Gain Therapeutics shares in Q1 2026, an estimated $38.6K.
Sprott Inc first reported a position in Gain Therapeutics in Q4 2024 and held it in 3 quarters.
Sprott Inc's Gain Therapeutics position peaked at $38.6K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Sprott Inc's 13F filing for Q1 2026, filed 8 May 2026.